Rigel Pharmaceuticals, Inc.Find Ratings Reports
RIGEL PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2021 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. RIGEL PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.67 which clearly shows the ability to cover any short-term cash needs. RIGL managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 2.52% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY21||Q3 FY20|
|Net Sales ($mil)||21.54||18.39|
|Net Income ($mil)||-20.95||-14.17|
|Balance Sheet||Q3 FY21||Q3 FY20|
|Cash & Equiv. ($mil)||143.15||72.81|
|Total Assets ($mil)||186.52||123.06|
|Total Debt ($mil)||98.13||41.1|
|Profitability||Q3 FY21||Q3 FY20|
|Gross Profit Margin||-90.63||-74.04|
|Return on Assets||-7.77||-22.51|
|Return on Equity||-29.21||-54.38|
|Debt||Q3 FY21||Q3 FY20|
|Share Data||Q3 FY21||Q3 FY20|
|Shares outstanding (mil)||170.97||168.94|
|Div / share||0.0||0.0|
|Book value / share||0.29||0.3|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1284442.0||1802691.0|
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 10.15 indicates a significant premium versus the S&P 500 average of 4.74 and a discount versus the subsector average of 10.99. The price-to-sales ratio is above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, RIGEL PHARMACEUTICALS INC proves to trade at a discount to investment alternatives.
|RIGL NM||Peers 35.44||RIGL 54.11||Peers 21.78|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
RIGL's P/E is negative making this valuation measure meaningless.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
RIGL is trading at a significant premium to its peers.
|RIGL NM||Peers 19.02||RIGL NA||Peers 1.05|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
RIGL's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|RIGL 10.15||Peers 10.99||RIGL 40.00||Peers 55.21|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
RIGL is trading at a valuation on par with its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, RIGL is expected to significantly trail its peers on the basis of its earnings growth rate.
|RIGL 3.42||Peers 78.20||RIGL 39.50||Peers 500.96|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
RIGL is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
RIGL significantly trails its peers on the basis of sales growth.